Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical (SNPHY)
:SNPHY
RESEARCH TOOLSreports
SNPHY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.88 - $12.89
Previous CloseN/A
Volume180.00
Average Volume (3M)2.43K
Market Cap
$3.58B
Enterprise Value$3.54B
Total Cash (Recent Filing)$93.99B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)17.1
Beta0.08
Next Earnings
Nov 11, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 28, 2023Dividend Yield1.6%
Share Statistics
EPS (TTM)0.12
Shares Outstanding342,059,540
10 Day Avg. Volume1,584
30 Day Avg. Volume2,430
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SNPHY FAQ
What was Santen Pharmaceutical’s price range in the past 12 months?
Santen Pharmaceutical lowest stock price was $8.88 and its highest was $12.89 in the past 12 months.
What is Santen Pharmaceutical’s market cap?
Santen Pharmaceutical’s market cap is $3.58B.
When is Santen Pharmaceutical’s upcoming earnings report date?
Santen Pharmaceutical’s upcoming earnings report date is Nov 11, 2025 which is in 87 days.
How were Santen Pharmaceutical’s earnings last quarter?
Santen Pharmaceutical released its earnings results on Aug 07, 2025. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of N/A by $0.12.
Is Santen Pharmaceutical overvalued?
According to Wall Street analysts Santen Pharmaceutical’s price is currently Overvalued.
Does Santen Pharmaceutical pay dividends?
Santen Pharmaceutical pays a Semiannually dividend of $0.076 which represents an annual dividend yield of 1.6%. See more information on Santen Pharmaceutical dividends here
What is Santen Pharmaceutical’s EPS estimate?
Santen Pharmaceutical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Santen Pharmaceutical have?
Santen Pharmaceutical has 342,059,540 shares outstanding.
What happened to Santen Pharmaceutical’s price movement after its last earnings report?
Santen Pharmaceutical reported an EPS of $0.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.177%.
Which hedge fund is a major shareholder of Santen Pharmaceutical?
Currently, no hedge funds are holding shares in SNPHY
Santen Pharmaceutical Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.70%
12-Months-Change
Fundamentals
Return on Equity
10.89%
Trailing 12-Months
Asset Growth
4.69%
Trailing 12-Months
Company Description
Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Technical Analysis
Ownership Overview
―
Insiders
0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---